BG60325B2 - Метод за откриване на инхибитори и активатори на протеин - Google Patents

Метод за откриване на инхибитори и активатори на протеин Download PDF

Info

Publication number
BG60325B2
BG60325B2 BG092673A BG9267390A BG60325B2 BG 60325 B2 BG60325 B2 BG 60325B2 BG 092673 A BG092673 A BG 092673A BG 9267390 A BG9267390 A BG 9267390A BG 60325 B2 BG60325 B2 BG 60325B2
Authority
BG
Bulgaria
Prior art keywords
protein
cell
cell line
cells
response
Prior art date
Application number
BG092673A
Other languages
Bulgarian (bg)
English (en)
Inventor
Gerard Housey
Original Assignee
Housey Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22550430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG60325(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Housey Pharmaceuticals, Inc. filed Critical Housey Pharmaceuticals, Inc.
Publication of BG60325B2 publication Critical patent/BG60325B2/bg

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BG092673A 1988-02-10 1990-08-10 Метод за откриване на инхибитори и активатори на протеин BG60325B2 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/154,206 US4980281A (en) 1988-02-10 1988-02-10 Method of screening for protein inhibitors and activators
PCT/US1989/000462 WO1989007654A1 (en) 1988-02-10 1989-02-09 Method of screening for protein inhibitors and activators

Publications (1)

Publication Number Publication Date
BG60325B2 true BG60325B2 (bg) 1994-05-27

Family

ID=22550430

Family Applications (1)

Application Number Title Priority Date Filing Date
BG092673A BG60325B2 (bg) 1988-02-10 1990-08-10 Метод за откриване на инхибитори и активатори на протеин

Country Status (18)

Country Link
US (1) US4980281A (da)
EP (1) EP0403506B1 (da)
JP (1) JPH03503598A (da)
AT (1) ATE140267T1 (da)
AU (1) AU612948B2 (da)
BG (1) BG60325B2 (da)
CA (1) CA1334927C (da)
DE (1) DE68926816T2 (da)
DK (2) DK189590A (da)
ES (1) ES2010131A6 (da)
FI (1) FI102618B1 (da)
HU (1) HU208555B (da)
IE (1) IE77332B1 (da)
IL (1) IL89227A (da)
MX (1) MX165993B (da)
NO (2) NO313103B1 (da)
RO (1) RO118452B1 (da)
WO (1) WO1989007654A1 (da)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688655A (en) * 1988-02-10 1997-11-18 Ict Pharmaceuticals, Inc. Method of screening for protein inhibitors and activators
US5266464A (en) * 1988-02-10 1993-11-30 Ict Pharmaceuticals, Inc. Method of screening for protein inhibitors and activators
EP0528827B1 (en) * 1990-04-19 1996-09-04 The General Hospital Corporation Protein partner screening assays and uses thereof
US5322801A (en) * 1990-04-19 1994-06-21 The General Hospital Corporation Protein partner screening assays and uses thereof
US6080540A (en) * 1990-04-20 2000-06-27 Cold Spring Harbor Laboratory Cloning of mammalian genes in microbial organisms and methods for pharmacological screening
FI931268L (fi) * 1990-09-24 1993-04-21 Gen Hospital Corp Saollningsfoerfaranden
US5707810A (en) * 1991-03-11 1998-01-13 Creative Biomolecules, Inc. Method of diagnosing renal tissue damage or disease
US5650276A (en) * 1991-03-11 1997-07-22 Creative Biomolecules, Inc. Morphogenic protein screening method
ATE250629T1 (de) * 1991-04-19 2003-10-15 Univ Washington Für säugetierphosphodiesterasen kodierende dns
US5747341A (en) * 1991-06-24 1998-05-05 Pacific Biomedical Research, Inc. Culture media having low osmolarity for establishing and maintaining hormone-secreting cells in long-term culture
EP0605428B9 (en) * 1991-06-24 2003-01-02 hCell Technology, Inc. Hormone-secreting pancreatic cells maintained in long-term culture
US5821121A (en) * 1991-06-24 1998-10-13 Pacific Biomedical Research, Inc. Hormone-secreting cells maintained in long-term culture
WO1993002209A1 (en) * 1991-07-22 1993-02-04 The Regents Of The University Of California Methods of designing specific affectors using three-dimensional conformation of enzyme/affector complex
AU696364B2 (en) * 1991-08-30 1998-09-10 Creative Biomolecules, Inc. Morphogenic protein screening method II
EP0825442A3 (en) * 1991-08-30 2004-02-11 Curis, Inc. Morphogenic protein screening method
GB9216654D0 (en) * 1992-08-05 1992-09-16 Imp Cancer Res Tech Transformed cells and assays using them
US6048850A (en) * 1992-09-22 2000-04-11 Young; Donald A. Method of inhibiting prostaglandin synthesis in a human host
US5837479A (en) * 1992-09-22 1998-11-17 Young; Donald A. Screening assays for inhibitors of mammalian prostaglandin H synthase-2
DE4306547C2 (de) * 1993-03-03 1996-07-11 Gsf Forschungszentrum Umwelt In-vitro-Test zur Detektion von Proteinkinase C Inhibitoren
JPH09501302A (ja) * 1993-04-07 1997-02-10 キャンサー リサーチ キャンペーン テクノロジー リミティド 治療活性についての物質のスクリーニングのための方法及びそれにおいて利用するための方法
US5776685A (en) * 1993-07-19 1998-07-07 Joslin Diabetes Center Protein kinase C assay
JPH09510104A (ja) * 1994-03-10 1997-10-14 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 形質転換の進行の誘導性阻害剤を同定する方法
DE69532127T2 (de) 1994-07-20 2004-08-26 Genetics Institute, Inc., Cambridge Interaktions-fullensysteme zum nachweis von protein-interaktionen
US6399296B1 (en) * 1994-07-20 2002-06-04 The General Hospital Corporation Interaction trap systems for detecting protein interactions
US5597697A (en) * 1994-09-30 1997-01-28 Diamond; Paul Screening assay for inhibitors and activators of RNA and DNA-dependent nucleic acid polymerases
KR100402836B1 (ko) * 1995-05-11 2004-02-19 주식회사 엘지생명과학 단백질간의상호작용을조절하는물질의새로운탐색시스템
US6365344B1 (en) * 1996-01-23 2002-04-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
DK0877752T3 (da) 1996-01-23 2003-09-15 Univ Leland Stanford Junior Fremgangsmåder til screening af transdominante effektorpeptider og RNA molekyler
US5928888A (en) * 1996-09-26 1999-07-27 Aurora Biosciences Corporation Methods and compositions for sensitive and rapid, functional identification of genomic polynucleotides and secondary screening capabilities
AU724107B2 (en) * 1997-01-31 2000-09-14 Fred Hutchinson Cancer Research Center Prognosis of cancer patients by determining expression of cell cycle regulators p27 and cyclin E
US7507705B2 (en) 1997-10-02 2009-03-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
WO1999024563A1 (en) 1997-11-07 1999-05-20 Iconix Pharmaceuticals, Inc. Surrogate genetics target characterization method
PL340433A1 (en) 1997-11-10 2001-02-12 Gen Hospital Corp Detection systems for detecting and recording protein-specific actions and functional interactions
US6362009B1 (en) 1997-11-21 2002-03-26 Merck & Co., Inc. Solid phase synthesis of heterocycles
US6811992B1 (en) * 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
US6518035B1 (en) 1998-06-02 2003-02-11 Rosetta Inpharmatics, Inc. Targeted methods of drug screening using co-culture methods
US6720139B1 (en) 1999-01-27 2004-04-13 Elitra Pharmaceuticals, Inc. Genes identified as required for proliferation in Escherichia coli
US6589738B1 (en) 1999-11-09 2003-07-08 Elitra Pharmaceuticals, Inc. Genes essential for microbial proliferation and antisense thereto
US6689558B2 (en) 2000-02-08 2004-02-10 Sangamo Biosciences, Inc. Cells for drug discovery
AU2001289284A1 (en) * 2000-04-04 2001-10-15 Enanta Pharmaceuticals, Inc. Methods for identifying peptide aptamers capable of altering a cell phenotype
CA2408743A1 (en) * 2000-05-25 2001-11-29 Curagen Corporation Method of detecting inflammatory lung disorders
WO2002000933A2 (en) * 2000-06-23 2002-01-03 Interleukin Genetics, Inc. Screening assays for identifying modulators of the inflammatory or immune responses
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
US20030170694A1 (en) * 2001-12-21 2003-09-11 Daniel Wall Stabilized nucleic acids in gene and drug discovery and methods of use
WO2003099222A2 (en) * 2002-05-23 2003-12-04 Invitrogen Corporation Pseudo-tissues and uses thereof
WO2004011496A2 (en) 2002-07-04 2004-02-05 Nalan Utku Novel t-cell proteins, peptides and antibodies derived therefrom and uses thereof
WO2004020666A2 (en) * 2002-09-02 2004-03-11 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of thyroid hormone binding protein for neurodegenerative diseases
US20050214292A1 (en) * 2002-10-18 2005-09-29 Wyeth Compositions and methods for diagnosing and treating autoimmune disease
DE602004015064D1 (de) * 2003-01-06 2008-08-28 Wyeth Corp Zusammensetzungen und verfahren zur diagnose und behandlung von kolonkrebs
WO2004070062A2 (en) * 2003-02-04 2004-08-19 Wyeth Compositions and methods for diagnosing and treating cancers
US20040191818A1 (en) * 2003-02-26 2004-09-30 O'toole Margot Mary Compositions and methods for diagnosing and treating autoimmune diseases
JP2007537984A (ja) * 2003-03-04 2007-12-27 ワイス 喘息または他のアレルギー性もしくは炎症性疾患の診断および治療のための組成物および方法
EP1620564A4 (en) * 2003-04-18 2008-03-12 Cytovia Inc METHOD FOR TREATING DISEASES RESPONSING TO APOPTOSIS INDUCTION AND SCREENING TESTS
US20050119210A1 (en) * 2003-05-20 2005-06-02 Xiaobing Be Compositions and methods for diagnosing and treating cancers
WO2005020902A2 (en) * 2003-08-21 2005-03-10 Cytokine Pharmasciences, Inc. Compositions and methods for treating and diagnosing irritable bowel syndrome
US20050164167A1 (en) * 2004-01-28 2005-07-28 Buscher Benjamin A. Method of discovery and development of broad-spectrum antiviral drugs
EP3461813A1 (en) * 2004-05-23 2019-04-03 Gerard M. Housey Theramutein modulators
US8431110B2 (en) 2005-05-23 2013-04-30 Hmi Medical Innovations, Llc. Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
CN103789389B (zh) 2005-11-23 2017-01-04 杰勒德·M·豪斯 鉴定、合成、优化和表征蛋白调节剂的化合物和方法
EP1878744A1 (en) * 2006-07-13 2008-01-16 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Epitope-tag for surface-expressed T-cell receptor proteins, uses thereof and method of selecting host cells expressing them
US20090285819A1 (en) * 2006-11-15 2009-11-19 Functional Genetics, Inc. Methods and compositions for treating influenza

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4480038A (en) * 1982-04-30 1984-10-30 E. I. Dupont De Nemours And Company Density separation of protein overproducing bacteria
US4532204A (en) * 1982-07-19 1985-07-30 Massachusetts Institute Of Technology Mutation assays involving blood cells that metabolize toxic substances
US5266464A (en) * 1988-02-10 1993-11-30 Ict Pharmaceuticals, Inc. Method of screening for protein inhibitors and activators

Also Published As

Publication number Publication date
JPH03503598A (ja) 1991-08-15
CA1334927C (en) 1995-03-28
DE68926816T2 (de) 1997-01-09
US4980281A (en) 1990-12-25
FI903918A0 (fi) 1990-08-08
EP0403506B1 (en) 1996-07-10
IL89227A0 (en) 1989-09-10
FI102618B (fi) 1999-01-15
HU208555B (en) 1993-11-29
NO20021142L (no) 1990-10-01
NO20021142D0 (no) 2002-03-07
DK189590D0 (da) 1990-08-09
DK189590A (da) 1990-10-02
MX165993B (es) 1992-12-15
DE68926816D1 (de) 1996-08-14
NO903494L (no) 1990-10-01
AU612948B2 (en) 1991-07-18
WO1989007654A1 (en) 1989-08-24
EP0403506A4 (en) 1991-07-24
ES2010131A6 (es) 1989-10-16
AU3184089A (en) 1989-09-06
IE890398L (en) 1989-08-10
IE77332B1 (en) 1997-12-02
NO903494D0 (no) 1990-08-08
FI102618B1 (fi) 1999-01-15
DK200100720A (da) 2001-05-08
RO118452B1 (ro) 2003-05-30
HUT55447A (en) 1991-05-28
EP0403506A1 (en) 1990-12-27
IL89227A (en) 1995-05-26
NO313103B1 (no) 2002-08-12
ATE140267T1 (de) 1996-07-15

Similar Documents

Publication Publication Date Title
BG60325B2 (bg) Метод за откриване на инхибитори и активатори на протеин
US5266464A (en) Method of screening for protein inhibitors and activators
US5688655A (en) Method of screening for protein inhibitors and activators
Goldberg et al. Activation of protein kinase C or cAMP‐dependent protein kinase increases phosphorylation of the c‐erbA‐encoded thyroid hormone receptor and of the v‐erbA‐encoded protein.
Feng et al. Transforming growth factor-β (TGF-β)-induced down-regulation of cyclin A expression requires a functional TGF-β receptor complex: characterization of chimeric and truncated type I and type II receptors
Renshaw et al. The human leukemia oncogene bcr-abl abrogates the anchorage requirement but not the growth factor requirement for proliferation
CA2166981C (en) Oncoprotein protein kinase
WO1995003323A9 (en) Oncoprotein protein kinase
US6863888B2 (en) Oncoprotein protein kinase
Parruti et al. Molecular cloning, functional expression and mRNA analysis of human beta-adrenergic receptor kinase 2
Kizaka-Kondoh et al. CrkII signals from epidermal growth factor receptor to Ras.
JP3372267B2 (ja) キメラ遺伝子
CA2112748A1 (en) A protein kinase associated with dna repair activity
US20110033911A1 (en) Episomal fusion gene
US6846644B2 (en) Oncoprotein protein kinase
WO2004033680A1 (en) Mutagenesis of drug binding region of proteins in methods of drug discovery
ITRM950434A1 (it) Polipeptide per la riparazione di informazione genetica, sequenza nucleotidica che codifica per esso e procedimento per la sua
US20060003434A1 (en) Mammalian endonucleases and methods of use
Mahoney Characterization of the HML silencers in Saccharomyces cerevisiae
Luo Cloning and expression of a bovine cDNA for the regulatory subunit (RIIbeta) of cAMP-dependent protein kinase and cloning and characterization of the mouse RIIbeta gene
McCright The identification and characterization of B56, a new family of protein phosphatase 2A regulatory subunits